MetaVia Inc.
MTVA
Κατάταξη σε μετοχές
#32859
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Τιμή μετοχής
$1.30
Τελευταίος συγχρονισμός: 2026-10-16
Κεφαλαιοποίηση
$8.53M
Αλλαγή (1 ημέρα)
-5.47%
Αλλαγή (1 έτος)
-20.55%
Χώρα
US
Εμπόριο MetaVia Inc. (MTVA)
Κατηγορία
Healthcare
Κεφαλαιοποίηση αγοράς του MetaVia Inc.(MTVA)
Κεφαλαιοποίηση: $8.53M
Μέχρι το October 2026, η MetaVia Inc. έχει χρηματιστηριακή αξία $8.53M. Αυτό καθιστά τη MetaVia Inc. την 32859th πιο πολύτιμη εταιρεία στον κόσμο βάσει της κεφαλαιοποίησης σύμφωνα με τα δεδομένα μας. Η χρηματιστηριακή κεφαλαιοποίηση είναι η συνολική αγοραία αξία των μετοχών μιας εισηγμένης εταιρείας και χρησιμοποιείται συνήθως για να προσδιοριστεί η αξία μιας εταιρείας.
Ιστορικό κεφαλαιοποίησης αγοράς της MetaVia Inc. από 2016 έως 2026
MTVA σε σύγκριση με τα 5 πιο δημοφιλή stocks
| Η τιμή για MTVA | Το περιουσιακό στοιχείο B | Η κεφαλαιοποίηση αγοράς του B | Αποτελέσματα | |
|---|---|---|---|---|
$505,878
$16.65M
|
$5.167T | +31,035,372.78% | ||
|
$490,971
$16.65M
|
$5.015T | +30,120,828.45% | ||
|
$402,232
$16.65M
|
$4.108T | +24,676,737.32% | ||
|
$382,015
$16.65M
|
$3.902T | +23,436,418.37% | ||
|
$263,311
$16.65M
|
$2.689T | +16,153,933.99% |
